Gilead Announces Response Data from Phase 2 Study of Idelalisib for …Fort Mills TimesGilead Sciences, Inc. (Nasdaq: GILD) today announced results from a Phase 2 study (Study 101-08) evaluating idelalisib (formerly GS-1101), an investigational, target…
Gilead Announces Response Data from Phase 2 Study of Idelalisib for …MarketWatch (press release)Gilead Sciences, Inc. (NASDAQ:GILD) today announced results from a Phase 2 study (Study 101-08) evaluating idelalisib (formerly GS-1101), an investigation…
|
Genentech Cancer Antibody, Son of Rituxan, Nails Pivotal Study
Xconomy Genentech has been searching for years to find a way to improve upon rituximab (Rituxan), which set a gold standard 15 years ago as part of the first generation of targeted antibody cancer drugs. Now it looks like Genentech has finally nailed a new and … Roche Experimental Leukemia Drug Helps Shrink TumorsBloomberg Genentech’s Obinutuzumab (GA101) Significantly Reduced the Risk of Disease …Wall Street Journal (press release) |
|
2 Scariest Dividend Stocks in Health Care
Motley Fool Let’s assume that multiple sclerosis drug daclizumab, developed with Biogen Idec (NASDAQ: BIIB ) , gains approval. Analysts estimate peak annual sales at $500 million on the high end. AbbVie splits profits equally with Biogen, so the drug would … |
WorldPoultry.netStudy: Cutting nitrogen emissions with egg yolk antibodiesWorldPoultry.netEgg yolk antibodies are economic alternatives for administering in feed to poultry. Supplementation of feed grade antibodies into poultry diets can be a potential…
|
Genentech to Present Important New Data Reflecting Broad Cancer Pipeline at …
The Herald | HeraldOnline.com The Phase III study CLL11, which is being conducted in close collaboration with the German CLL Study Group (GCLLSG), compared the combination of either GA101 or Rituxan® (rituximab) and standard chemotherapy (chlorambucil) to chlorambucil alone. |
Addition of rituximab to DA-EPOCH negated need for radiotherapy in primary …HealioThe addition of rituximab to dose-adjusted etoposide, doxorubicin, and cyclophosphamide plus vincristine and prednisone prevented the need for radiotherapy in most pati…
 Healthline |
What’s Driving the Surge in Drug Research for “Orphan” Diseases? – Healthline
Healthline For example, Biogen Idec’s drug Rituximab, a breakthrough treatment for B-cell lymphoma, is projected to generate $34 billion in revenue, according to Thomson Reuters. The drug has since proven helpful in treating rheumatoid arthritis, multiple … |
Competing Antibodies May Have Hindered Thai HIV VaccineAIDSmeds.com HIV/AIDS Treatment NewsNew research on the Thai HIV vaccine trial that was shuttered in 2009 has found that two of the antibodies the vaccine prompted actually worked against one anoth…
|
AbbVie grabs rights to biotech startup’s anti-gluten drug for $70M upfront
FierceBiotech AbbVie is partnered with biotech heavyweight Biogen Idec ($BIIB) on the development therapy for multiple sclerosis known as daclizumab, for instance, and the pharma company has grabbed rights to a drug from Enanta Pharmaceuticals ($ENTA) for use in … |